Key Market Indicator:
F&G: 52
25.060,90 NASDAQ · 48.594,00 DOW · 6.822,05 S&P · 4.786,50 Gold · 63,63 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
© Globe Newswire
15.01.2025
ISIN: FI0009014377
Orion Oyj
ORNBV
LISTED
HEL
Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2025 Annual General Meeting
Article
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE15 JANUARY 2025 at 10.45 EET           ...
Themefolio
Profiler
Peergroup
© EQS Newswire
15.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon und Fresenius Kabi geben die Zulassung von FYB202/Otulfi® (ustekinumab), einem Biosimilar zu Stelara®, durch die britische MHRA bekannt
Article
News Preview
Pressemitteilung // 15. Januar 2025 Formycon und Fresenius Kabi geben die Zulassung von FYB202/Otulfi® (ustekinumab), einem Biosimilar zu Stelara®, durch die britische MHRA bekannt Otulfi® hat die MHRA-Zulassung für subkutane und intravenöse Formulierungen zur Behandlung schwerer entzündlicher Erkrankungen erhalten Die Zulassung im Vereinigten K......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
Article
News Preview
Press Release // January 15, 2025 Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi®received MHRA approval for both subcutaneous and intravenous formulations, to treat serious inflammatory diseases UK approval follows the series of successful approvals by the FDA, the European Co......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ActuNews
14.01.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities LLC
Article
News Preview
Leuven, BELGIUM – January 14, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received an amended transparency notification as follows: Oxurion received a transparency notification on January 13, 20...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ActuNews
14.01.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion ontvangt aangepaste transparantiekennisgeving van Atlas Special Opportunities LLC
Article
News Preview
Leuven, BELGIË – 14 januari 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende aangepaste transparantiekennisgeving heeft ontvangen: Oxurion ontving ee...
Themefolio
Profiler
Peergroup
© EQS Newswire
14.01.2025
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture
Article
News Preview
Berlin, 14 January 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a licence agreement with Qi Kang Medical, Ltd (QKM), a joint venture between Eckert & Ziegler and the Chinese company DC Pharma, for the cyclotron technology used by Eckert & Ziegler to manufacture Ac-225. The contract guarantees Eckert & Ziegler a......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.01.2025
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler schließt Lizenzvertrag für Actinium-225 mit chinesischem Joint Venture
Article
News Preview
Berlin, 14. Januar 2025. Die Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) hat heute mit Qi Kang Medical, Ltd (QKM), einem Joint-Venture der Eckert & Ziegler und der chinesischen DC Pharma, einen Lizenzvertrag über die von Eckert & Ziegler verwendete Zyklotron-Technologie zur Herstellung von Ac-225 unterzeichnet. Der Vertrag sichert E......
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2025
ISIN: US2290503075
Cryoport Inc
CYRX
LISTED
NASDAQ
Moffitt Cancer Center and Cryoport Announce Strategic Collaboration
Article
News Preview
Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL, a 775-acre global innovation life sciences campus, a...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2025
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care
Article
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative capabilities available in Tempus One, the company’s generative AI assistant. Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2025
ISIN: IE0005711209
ICON PLC
ICLR
LISTED
NASDAQ
ICON Issues Financial Guidance for Full Year 2025
Article
News Preview
ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025. For the full year 2025, revenue is expected to be in the range of $8,050 - $8,650 million, representing growth of approximately 1% at the midpoint and adjusted ea...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2025
ISIN: GB00B0LCW083
Hikma Pharmaceuticals PLC
HIK
LISTED
LSE
Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg
Article
News Preview
LONDON, Jan. 14, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (Emergent) for the sale of KLOXXADO® naloxone HCl nasal spray 8 mg in the U.S. and Canada. KLOXXADO® was approved by the US Food and Dru...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2025
ISIN: GB0009223206
Smith & Nephew PLC
SN
LISTED
LSE
Smith+Nephew’s ALLEVYN™ LIFE Sacrum Foam Dressing and LEAF™ Patient Monitoring System receive ‘favorable’ Evidence Bar™ ratings from ECRI for pressure injury prevention
Article
News Preview
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that ECRI – leaders in advancing evidence-based healthcare globally - have completed updated Clinical Evidence Assessments of ALLEVYN LIFE Sacrum Foam Dressings and the LEAF Patient Monitoring System. In their latest reports, ECRI upgraded its Evidence Bar ratin...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
14.01.2025
ISIN: US45783C2008
Instil Bio Inc
TIL
LISTED
NASDAQ
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
Article
News Preview
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
Article
News Preview
STOCKHOLM, Jan. 14, 2025 /PRNewswire/ --BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosingLeqembi is indicated for the treatment of Al...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
Article
News Preview
STOCKHOLM, Jan. 13, 2025 /PRNewswire/ --BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosingLeqembi is indicated for the treatment of Al...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
ISIN: FR0004163111
Genfit SA
GNFT
LISTED
EURONEXT
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
Article
News Preview
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 13 janvier 2025 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui le bilan semestriel du contra...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
ISIN: FR0010417345
Dbv Technologies SA
DBV
LISTED
EURONEXT
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Article
News Preview
AMF Regulated InformationChâtillon, France, January 13, 2025...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.01.2025
ISIN: CH0012549785
Sonova Holding AG
SOON
LISTED
SIX
Sonova to present at the J.P. Morgan 2025 Healthcare Conference
Article
News Preview
Sonova Holding AG / Key word(s): Conference Sonova to present at the J.P. Morgan 2025 Healthcare Conference 13.01.2025 / 18:00 CET/CEST Group Media & Investor Release Staefa (Switzerland), January 13, 2025 – Sonova Holding AG (SWX: SOON), a leading provider of innovative hearing solutions, announces that its Chief E......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.01.2025
ISIN: CH0012549785
Sonova Holding AG
SOON
LISTED
SIX
Sonova präsentiert auf der J.P. Morgan 2025 Healthcare Conference
Article
News Preview
Sonova Holding AG / Schlagwort(e): Konferenz Sonova präsentiert auf der J.P. Morgan 2025 Healthcare Conference 13.01.2025 / 18:00 CET/CEST Group Media & Investor Release Staefa (Schweiz), 13. Januar 2025 – Sonova Holding AG (SWX: SOON), ein führender Anbieter innovativer Hörlösungen, gibt bekannt, dass CEO Arnd Kald......
Themefolio
Profiler
Peergroup
© ActuNews
13.01.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC
Article
News Preview
Leuven, BELGIË – 13 januari 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen: Oxurion ontving een transpara...
Themefolio
Profiler
Peergroup
© ActuNews
13.01.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Article
News Preview
Leuven, BELGIUM – January 13, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on January 13, 2025, from...
Themefolio
Profiler
Peergroup
© ActuNews
13.01.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
OXURION : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
Article
News Preview
Atlas Special Opportunities, LLC heeft 4 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 100.000. Deze conversie vormt deel van Atlas Special Opportunities, LLC's EUR 20 miljoen kapitaaltoezegging1 die aan Oxurion zal toelaten om te focussen op het ontwikkelen van innovatieve geneesmiddelen om he...
Themefolio
Profiler
Peergroup
© ActuNews
13.01.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
OXURION : Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Article
News Preview
Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential ma...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer
Article
News Preview
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Article
News Preview
Company announcement – No. 1 / 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
ISIN: DE0005313704
Carl Zeiss Meditec AG
AFX
LISTED
XETR
ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow
Article
News Preview
The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE pro, extending ZEISS' LVC market leadership with treatment for myopia, hyperopia, and mixed astigmatism. DUBLIN, Calif. and JENA, Germany, Jan. 13, 2025 /CNW/ -- ZEISS Medical Technology announced today that the MEL® 90 received approval from the U.S. Food and Drug Administratio...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Tempus Announces Preliminary Fourth Quarter and Full Year 2024 Results
Article
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Select, Preliminary, Unaudited Financial Results Revenue of approximately $693 millio...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
ISIN: US8292141053
Simulations Plus Inc
SLP
LISTED
NASDAQ
Simulations Plus Supported Development of Every FDA-Approved Drug in 2024
Article
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today highlighted its impact on the pharmaceutical industry through supporting the development of 100% of the drugs approve...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
ISIN: CA23256X4075
Cybin Inc.
HELP
LISTED
NASDAQ
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
Article
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to provide a year-end summary of its key accomplishments in 2024 and upcoming milestones for 2...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.01.2025
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler und GlyTherix erweitern Zusammenarbeit mit Liefervertrag für Actinium-225
Article
News Preview
Berlin, Deutschland und Sydney, Australien, 13. Januar 2025. Eckert & Ziegler (ISIN DE0005659700, SDAX) und GlyTherix Ltd (GlyTherix), ein australisches Unternehmen für zielgerichtete Strahlentherapie, das auf die Entwicklung von Antikörper-Radiopharmaka zur Behandlung von soliden Tumoren spezialisiert ist, gaben heute die Erweiterung ihrer bes......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.01.2025
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
Article
News Preview
Berlin, Germany and Sydney, Australia, 13. January 2025. Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today announced the expansion of their existing Lutetium-177 based collaboration with a global s......
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
ISIN: FI0009014377
Orion Oyj
ORNBV
LISTED
HEL
79,345 Orion Corporation A shares converted into B shares
Article
News Preview
ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE13 JANUARY 2025 at 9.50 EET          ...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Teva wird strategischer Vermarktungspartner für Formycons Biosimilar-Kandidat FYB203 (Eylea®/ Aflibercept) in weiten Teilen Europas und Israel
Article
News Preview
Pressemitteilung // 13. Januar 2025   Teva wird strategischer Vermarktungspartner für Formycons Biosimilar-Kandidat FYB203 (Eylea®/ Aflibercept) in weiten Teilen Europas und Israel   Planegg-Martinsried – Die Klinge Biopharma GmbH (Klinge), Lizenznehmer und exklusiver Inhaber der weltweiten Vermarktungsrechte für FYB203, Formycons Biosimilar-Kand......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
Article
News Preview
Presse Release // January 13, 2025   Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel Planegg-Martinsried, Germany – Klinge Biopharma GmbH (Klinge), the licensee and exclusive global commercialization rights holder for FYB203, Formycon’s biosimila......
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2025
ISIN: US04351P1012
Ascendis Pharma A/S
ASND
LISTED
NASDAQ
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference
Article
News Preview
- Ascendis positioned to drive rapid revenue growth...
Themefolio
Profiler
Peergroup
© PR Newswire
10.01.2025
ISIN: US68232V8019
Traws Pharma Inc.
TRAW
LISTED
NASDAQ
Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program
Article
News Preview
SAN DIEGO, Jan. 10, 2025 /PRNewswire/ -- Expert Systems, a hybrid AI enabled drug discovery and development accelerator, announced a significant milestone in a development of Traws Pharma, Inc. 's (NASDAQ: TRAW) H5N1 antiviral program. The investigational drug, Tivoxavir Marboxil, has shown encouraging results as a single-dose treatment for H5N...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.01.2025
ISIN: BE0003766806
Ion Beam Applications SA
IBAB
LISTED
EURONEXT
Ensuring the continuity of IBA's Entrepreneurial Anchoring
Article
News Preview
Confirmation of the sale of IBA shares to Management Anchorage...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2025
ISIN: US98887Q1040
Zai Lab Limited
ZLAB
LISTED
NASDAQ
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
Article
News Preview
Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a rec...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.01.2025
ISIN: ES0167733015
Oryzon Genomics SA
ORY
LISTED
BME
ORYZON to Provide Corporate Progress Updates at Several Events in January-February
Article
News Preview
MADRID and CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several internation...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.01.2025
ISIN: US45258D1054
Immunocore Holdings plc
IMCR
LISTED
NASDAQ
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Article
News Preview
 Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.01.2025
ISIN: DK0060055861
Chemometec A/S
CHEMM
LISTED
CPH
Upgrade of revenue and operating profit guidance
Article
News Preview
ANNOUNCEMENT NO. 286...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2025
ISIN: US98887Q1040
Zai Lab Limited
ZLAB
LISTED
NASDAQ
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
Article
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) to use MediLink’s TMALIN® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab. Th...
Themefolio
Profiler
Peergroup
© BusinessWire
09.01.2025
ISIN: CA23256X4075
Cybin Inc.
HELP
LISTED
NASDAQ
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Article
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a firesid...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2025
ISIN: IE000LK2BOB4
Mural Oncology PLC
MURA
LISTED
NASDAQ
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Article
News Preview
Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma...
Themefolio
Profiler
Peergroup
© ActuNews
09.01.2025
ISIN: FR0013286259
Theranexus SA
ALTHX
LISTED
EURONEXT
THERANEXUS ANNOUNCES THE PUBLICATION OF ITS LETTER TO SHAREHOLDERS
Article
News Preview
Lyon, France – January 9, 2025, 6:00 PM CET - Theranexus, an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces the publication of its letter to shareholders. To download the newsletter, click here. This letter is also available on the Theranexus website (link), in the Shareholders/Financial D...
Themefolio
Profiler
Peergroup
© ActuNews
09.01.2025
ISIN: FR0013286259
Theranexus SA
ALTHX
LISTED
EURONEXT
THERANEXUS ANNONCE LA PUBLICATION DE SA LETTRE AUX ACTIONNAIRES
Article
News Preview
Lyon, France – 9 janvier 2025, 18h00 CET - Theranexus, société biopharmaceutique innovante dans le traitement des maladies neurologiques rares, annonce ce jour la publication de sa lettre aux actionnaires. Pour télécharger la newsletter, cliquez ici. Cette lettre est également consultable sur le site interne...
Themefolio
Profiler
Peergroup
© EQS Newswire
09.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon included in TecDAX Index of Deutsche Börse
Article
News Preview
Press Release // January 9, 2025   Formycon included in TecDAX Index of Deutsche Börse Formycon to join the ranks of the 30 leading listed technology companies Uplisting to the Prime Standard, inclusion in the SDAX, and robust business development further enhance the stock’s appeal Entry into the TecDAX becomes effective as of January 13, 2025 ......
Themefolio
Profiler
Peergroup
© EQS Newswire
09.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon wird in den TecDAX der Deutschen Börse aufgenommen
Article
News Preview
Pressemitteilung // 09. Januar 2025   Formycon wird in den TecDAX der Deutschen Börse aufgenommen Formycon gehört künftig zu den 30 gelisteten Top-Technologiewerten Uplisting in den Prime Standard, Aufstieg in den SDAX und erfolgreiche Geschäftsentwicklung fördern die Attraktivität der Aktie Aufnahme in den TecDAX ab 13. Januar 2025 wirksam Pla......
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2025
ISIN: SE0002190926
Karolinska Development AB
KDEV
LISTED
STO
Karolinska Development’s portfolio company AnaCardio raises SEK 205 million and reports positive Phase 1b data of AC01
Article
News Preview
STOCKHOLM, SWEDEN January 9, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has secured SEK 205 million in a series A extension financing round and reports positive results from the first part of a Phase 1b/2a study of AC01 in patients with heart failure and reduced ejection fraction. T...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2025
ISIN: DK0015998017
Bavarian Nordic A/S
BAVA
LISTED
CPH
Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million
Article
News Preview
COPENHAGEN, Denmark, January 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a share buy-back program of up to DKK 150 million as announced on December 11, 2024. The decision to launch the program is driven by a better-than-expected performance and improved visibility pertaining to the Company’s Travel Health business, w...
Themefolio
Profiler
Peergroup
© Newsfile
09.01.2025
ISIN: NL0011832936
Cosmo Pharmaceuticals NV
COPN
LISTED
SIX
Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
Article
News Preview
Ad hoc announcement pursuant to Art. 53 LR Revenue Growth: Full-year 2024 revenue of €265.7 million (unaudited), marking a 186% increase compared to 2023. Financial Strength: Year-end cash and short-term investments of €170.4 million, reflecting a robust balance sheet with zero debt....
Themefolio
Profiler
Peergroup
© EQS Newswire
09.01.2025
ISIN: CH0012549785
Sonova Holding AG
SOON
LISTED
SIX
Sonova gibt personelle Veränderungen im Verwaltungsrat bekannt
Article
News Preview
Sonova Holding AG / Schlagwort(e): Personalie Sonova gibt personelle Veränderungen im Verwaltungsrat bekannt 09.01.2025 / 06:59 CET/CEST Group Media & Investor Release Der Verwaltungsrat hat Laura Stoltenberg als neues Mitglied für die Wahl an der nächsten ordentlichen Generalversammlung (GV) im Juni 2025 nominiert.......
Themefolio
Profiler
Peergroup
© EQS Newswire
09.01.2025
ISIN: CH0012549785
Sonova Holding AG
SOON
LISTED
SIX
Sonova announces changes to its Board of Directors
Article
News Preview
Sonova Holding AG / Key word(s): Personnel Sonova announces changes to its Board of Directors 09.01.2025 / 06:59 CET/CEST Group Media & Investor Release The Board of Directors (the Board) has nominated Laura Stoltenberg for election as a new member at the upcoming Annual General Meeting (AGM) in June 2025. She succe......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
Article
News Preview
Press Release // January 8, 2025 Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi® approved by Health Canada for both subcutaneous and intravenous formulations to treat serious inflammatory diseases Health Canada joins the FDA and the European Commission in gra......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon und Fresenius Kabi Canada erhalten Zulassung von Health Canada für FYB202/Otulfi® (Ustekinumab), ein Biosimilar zu Stelara®
Article
News Preview
Pressemitteilung // 08. Januar 2025 Formycon und Fresenius Kabi Canada erhalten Zulassung von Health Canada für FYB202/Otulfi® (Ustekinumab), ein Biosimilar zu Stelara® Otulfi® wurde von Health Canada für subkutane und intravenöse Formulierungen zur Behandlung schwerer entzündlicher Erkrankungen zugelassen Health Canada schließt sich der FDA un......
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia AB (Publ) presents Nomination Committee
Article
News Preview
LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.  According to the instructions for the Nomination Committee of Immunovia AB (Publ), the Nomination Committee shall consist of four members, of which thr...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia AB (Publ) presents Nomination Committee
Article
News Preview
LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.  According to the instructions for the Nomination Committee of Immunovia AB (Publ), the Nomination Committee shall consist of four members, of which thr...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2025
ISIN: IE0005711209
ICON PLC
ICLR
LISTED
NASDAQ
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey
Article
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for A...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2025
ISIN: BE0003818359
Galapagos NV
GLPG
LISTED
EURONEXT
Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities
Article
News Preview
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2025
ISIN: US74039M3097
Predictive Oncology, Inc.
POAI
LISTED
NASDAQ
PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI
Article
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Predictive Oncology Inc. (NasdaqCM: POAI) to Renovaro Inc. (NasdaqCM: RENB). Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Wednesday, 21.01.2026, Calendar Week 04, 21st day of the year, 344 days remaining until EoY.